RNA enzymes (ribozymes) as antiviral therapeutic agents
- PMID: 1366622
- DOI: 10.1016/0167-7799(90)90169-x
RNA enzymes (ribozymes) as antiviral therapeutic agents
Abstract
Among the landmark discoveries of recent years are ribozymes, RNA molecules which possess enzymatic, self-cleaving activities. The concept of exploiting the ribozyme catalytic center for cleaving (inactivating) a specific RNA transcript is now emerging as a potential therapeutic or preventative strategy in human diseases, veterinary medicine and agriculture. Linked to the catalytic center of the ribozyme are RNA sequences which are complementary to, and thus serve to target the ribozyme to, a unique RNA sequence. Specific association of the ribozyme with its target via base pairing, cleavage of the RNA substrate and subsequent recycling of the ribozyme make these catalytic RNA molecules attractive as antiviral agents. Theoretically, ribozymes can be adapted for the destruction of any RNA species, whatever its origin.
Similar articles
-
Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems.AIDS Res Hum Retroviruses. 1992 Feb;8(2):183-9. doi: 10.1089/aid.1992.8.183. AIDS Res Hum Retroviruses. 1992. PMID: 1540406 Review.
-
Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents.Antisense Res Dev. 1991 Fall;1(3):285-8. Antisense Res Dev. 1991. PMID: 1821650 Review.
-
Antiviral activity of RNA molecules containing self-releasing ribozymes targeted to lymphocytic choriomeningitis virus.Antisense Res Dev. 1995 Fall;5(3):203-12. doi: 10.1089/ard.1995.5.203. Antisense Res Dev. 1995. PMID: 8785476
-
The potential use of catalytic RNAs in therapy of HIV infection and other diseases.Pharmacol Ther. 1991;50(2):245-54. doi: 10.1016/0163-7258(91)90016-f. Pharmacol Ther. 1991. PMID: 1763136 Review.
-
Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents.Adv Exp Med Biol. 1992;312:95-109. doi: 10.1007/978-1-4615-3462-4_9. Adv Exp Med Biol. 1992. PMID: 1514448 Review. No abstract available.
Cited by
-
XNAzymes targeting the SARS-CoV-2 genome inhibit viral infection.Nat Commun. 2022 Nov 16;13(1):6716. doi: 10.1038/s41467-022-34339-w. Nat Commun. 2022. PMID: 36385143 Free PMC article.
-
Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better.Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):6921-5. doi: 10.1073/pnas.88.16.6921. Proc Natl Acad Sci U S A. 1991. PMID: 1871108 Free PMC article.
-
Selective cleavage of closely-related mRNAs by synthetic ribozymes.Nucleic Acids Res. 1992 Feb 25;20(4):831-7. doi: 10.1093/nar/20.4.831. Nucleic Acids Res. 1992. PMID: 1347418 Free PMC article.
-
Antiviral ribozymes. New jobs for ancient molecules.Mol Biotechnol. 1997 Aug;8(1):17-33. doi: 10.1007/BF02762337. Mol Biotechnol. 1997. PMID: 9327395 Review.
-
Inhibition of gene expression with ribozymes.Cell Mol Neurobiol. 1994 Oct;14(5):523-38. doi: 10.1007/BF02088835. Cell Mol Neurobiol. 1994. PMID: 7621511 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources